CME: Who’s on first, and going beyond platinum: strategies for optimizing treatment of extensive-stage small cell lung cancer each step of the way
ACCREDITATION EXPIRED: October 31, 2024
Activity Description / Statement of Need:
In this online, self-learning activity:
Lung cancer is the leading cause of cancer-related death in the United States, with more than 238,000 new cases diagnosed and over 127,000 deaths annually. The most common type of lung cancer, non–small cell lung cancer (NSCLC), accounts for about 85% of cases and has seen steady declines in mortality over the past several years as improvements have been made in diagnosis, staging, and treatment. In contrast, outcomes for the less prevalent small cell lung cancer (SCLC), which is neuroendocrine in nature and accounts for about 14% of all lung cancer cases, have remained poor in recent years despite improvement in those for NSCLC.
Target Audience:
HCPs including: oncology, pulmonology, and pathology; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and any other HCPs with an interest in or who clinically encounter patients with SCLC.
Commercial Support Disclosure: This program is supported by an educational grant from Jazz Pharmaceuticals.
This activity is free of charge.
Release Date: October 31, 2023 -- Expiration Date: October 31, 2024
Faculty: Sandip Patel, MD
Agenda
|
Introduction, Disclosures |
|
SCLC: Pathophysiology and Epidemiology
|
|
Systemic Therapy in SCLC
|
|
Summary, conclusions, and best practice recap |
Learning Objectives
By the end of the session the participant will be able to:
- Describe best practices in the identification of extensive-stage SCLC, and apply that information to a patient case.
- Outline the role of different treatment modalities for extensive-stage SCLC.
- Formulate a treatment plan for a patient with extensive-stage SCLC.
Accreditation
ACCME Activity #202572903
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.
Disclosure of Faculty: Sandip Patel, MD, Professor, Medical Oncology, UC San Diego, has received financial compensation for consulting from Amgen, AstraZeneca, BeiGene, Bristol-Myers Squibb, Certis, Eli Lilly, Jazz, Genentech, Illumina , Merck, Pfizer, Rakuten, Signatera, Tempus; and grant research support from: Amgen, AstraZeneca/MedImmune, Bristol-Myers Squibb, Eli Lilly, Fate Therapeutics, Gilead, Iovance, Merck, Pfizer, Roche/Genentech, SQZ Biotechnologies
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
Faculty WILL NOT discuss off-label uses.
All relevant financial relationships have been mitigated.
ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Commercial Support Disclosure: This program is supported by an educational grant from Jazz Pharmaceuticals.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Additional Courses That Are Related To This Activity
Advanced systemic mastocytosis: from recognition to treatment
Contemporary treatment approaches in the management of graft-versus-host disease (GVHD)